Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 105 publications.
Skip to main content
MacDonald SC, Rivero-Ferrer E, Bell EJ, Franklin J, Hardy J, Margulis AV, Seals R, Yang R, Seeger J, Straghan E, Asomaning K. A retrospective cohort database study to evaluate the safety of rimegepant exposure during pregnancy. Poster to be given at the 38th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research; June 9, 2025. Boston, MA.
Riera-Guardia N, Margulis AV, Calingaert B, Fletcher MP, Patki K, Weiner E, Armstrong R, Rivero-Ferrer E. Fetal and neonatal alloimmune thrombocytopenia: systematic literature review and challenges encountered. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Jacobson MH, Sabido M, Afonso AS, Ajao A, Alghamdi EA, Andrade S, Bennett D, Kharat V, Kurzinger ML, Le Noan-Laine M, Molgaard-Nielsen D, Murray G, Rivero-Ferrer E, Lopez-Leon S. Algorithms to identify major congenital malformations in routinely collected healthcare databases: a systematic literature review. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Broe A, Willis SK, Dareng E, Haviland M, van Gelder MMHJ, Nordeng HME, Wood ME, Sahin L, Margulis AV, Rivero-Ferrer E. Building global consensus on definitions for drug safety studies in pregnancy to improve harmonized evaluation of real-world data. Presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Forns J, Abellan A, Riera-Guardia N, Margulis AV, Rivero-Ferrer E. Identification of migraine in electronic healthcare data sources: a headache for pharmacoepidemiologists – a systematic literature review. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Margulis AV, Riera-Guardia N, Calingaert B, Armstrong R, Fletcher M, Patki K, Weiner E, Rivero-Ferrer E. Fetal and neonatal alloimmune thrombocytopenia: a systematic literature review and meta-analysis of adverse pregnancy-related outcomes to support the development of a novel prophylactic therapeutic. Poster presented at the AMCP Annual Meeting 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-a):S96-7. doi: 10.18553/jmcp.2024.30.4-a.s1
Margulis AV, Calingaert B, Kawai AT, Rivero-Ferrer E, Anthony MS. Distribution of gestational age at birth by maternal and infant characteristics in U.S. birth certificate data: informing gestational age assumptions when clinical estimates are not available. Pharmacoepidemiol Drug Saf. 2023 Sep;32(9):1012-20. doi: 10.1002/pds.5633
Margulis AV, Calingaert B, Kawai AT, Rivero-Ferrer E, Anthony MS. Distribution of gestational age by maternal and infant characteristics in US birth certificate data: toward informing gestational age assumptions when clinical estimates are not available. Poster presented at the 2022 ICPE Conference; August 26, 2022. Copenhagen, Denmark.
Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997
Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E. Acute myocardial infarction, stroke, and MACE in COPD patients treated with aclidinium and other inhaled bronchodilators. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman BA, Garcia de Albeniz X. The effect of continuous use of antidepressants, with or without anticholinergic properties, for at least 4 months versus no treatment on the incidence of dementia: a target trial emulation. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Margulis AV, Kawai AT, Anthony MS, Rivero-Ferrer E. Perinatal pharmacoepidemiology: how often are key methodological elements reported in publications? Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):61-71. doi: 10.1002/pds.5353
Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman B, Garcia de Albaniz X. The effect of the anticholinergic properties of antidepressants on the incidence of dementia: a target trial emulation. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624
Rebordosa C, Rubino A, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi N, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rivero-Ferrer E. Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries. Poster presented at the 2020 Virtual ERS International Congress; October 2020. [abstract] Eur Respir J. 2020 Oct 28; 56(Suppl 64):2071. doi: 10.1183/13993003.congress-2020.2072
Zografos L, Rivero-Ferrer E, Abramsky S, Lou J, Davenport E, Wolin D. Evaluation of the physician education component of the ozurdex risk management plan. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Margulis AV, Kawai AT, Anthony M, Rivero-Ferrer E. Pregnancy pharmacoepidemiology: how often are key methodological data elements reported in publications? Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Rivero-Ferrer E, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rebordosa C. Are aclidinium and aclidinium/formoterol used according to their approved indication in Europe? Results of a multicountry drug utilization postauthorization safety study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Salem L, Malouvier A, Blatchford J, Rivero‐Ferrer E, Deltour N, Jacquot E. Ivabradine drug utilization study in five European countries: a multinational, retrospective, observational study to assess effectiveness of risk‐minimization measures. Pharmacoepidemiol Drug Saf. 2019 Nov;28(11):1470-9. doi: 10.1002/pds.4880
Margulis AV, Anthony M, Rivero-Ferrer E. Drug safety in pregnancy: review of study approaches requested by regulatory agencies. Curr Epidemiol Rep. 2019 Sep;6(3):380-9. doi: 10.1007/s40471-019-00212-6
Plana E, Rivero-Ferrer E, Aguado J, Saigi-Morgui N, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rebordosa C. Hospitalization for heart failure among patients using aclidinium bromide and other COPD medications: a post-authorisation safety study in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1153. doi: 10.1002/pds.4864
Saigi N, Rebordosa C, Bui C, Aguado J, Plana E, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rivero-Ferrer E. A validation exercise: identifying hospitalizations for heart failure among patients with COPD in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):334. doi: 10.1002/pds.4864
Salem L, Malouvier A, Blatchford J, Rivero-Ferrer E, Deltour N, Jacquot E. Ivabradine drug utilization study in five European countries: a PASS to assess effectiveness of risk-minimization measures. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):450. doi: 10.1002/pds.4864
Cainzos-Achirica M, Rebordosa C, Vela E, Cleries M, Matsushita K, Plana E, Rivero-Ferrer E, Enjuanes C, Jimenez-Marrero S, Garcia-Rodriguez LA, Comin-Colet J, Perez-Gutthann S. Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. Am Heart J. 2018 Aug;202:76-83. doi: 10.1016/j.ahj.2018.05.005
Rivero-Ferrer E, Martinez D, Rasouliyan L, Anthony MS, Margulis AV, Perez-Gutthann S. Do ICPE pregnancy abstracts make it to term? Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):241. doi: 10.1002/pds.4629
Rivero-Ferrer E, Castellsague J, Aguado J, Plana E, Saigi N, Garcia-Gil E, Perez-Gutthann S, Rebordosa C. Are you really dead? Validation of death and date of death in patients with COPD in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):122-3. doi: 10.1002/pds.4629
Didden E-M, Andrews EB, Hellwig K, Hernandez-Diaz S, Magyari M, Margulis AV, Rivero-Ferrer E, Bader-Weder S, Wormser D. A novel approach for active surveillance of pregnancy safety in multiple sclerosis. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):268. doi: 10.1002/pds.4629
Margulis A, Andrews E, Hernandez-Diaz S, Magyari M, Rivero-Ferrer E, Bader-Weder S, Evershed J, Garas M, Wang Q, Wormser D. Design of a multi-source post-marketing study to evaluate pregnancy and infant outcomes in women with multiple sclerosis who were exposed to ocrelizumab during, or within 6 months before, pregnancy. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 25, 2018. Los Angeles, CA.
Krueger WS, Anthony MS, Saltus CW, Margulis AV, Rivero-Ferrer E, Monz B, Hirst C, Wormser D, Andrews E. Evaluating the safety of medication exposures during pregnancy: a case study of study designs and data sources in multiple sclerosis. Drugs Real World Outcomes. 2017 Sep;4(3):139-49. doi: 10.1007/s40801-017-0114-9
Krueger WS, Anthony MS, Saltus CW, Margulis AV, Rivero-Ferrer E, Monz B, Wormser D, Andrews E. Existing databases useful for pregnancy exposure and fetal outcomes research, case study in multiple sclerosis (MS). Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):403. doi: 10.1002/pds
Anthony M, Calingaert B, McQuay LJ, Andrews E, McGrath L, Rothman KJ, Rivero-Ferrer E. Suicide, suicidal behavior, and mortality rates in patients with psoriasis in England. Presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):475. doi: 10.1002/pds
Martín-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia Rodriguez LA. Risk factors for diabetic macular oedema in type 2 diabetes: a case-control study in a United Kingdom primary care setting. Prim Care Diabetes. 2017 Jun;11(3):288-96. doi: 10.1016/j.pcd.2017.03.002
Farrar J, Rivero E, Silman A, Hochberg M, Pandhi S, Banerjee S, Kahler K, Hunter S, Candrilli S, Castellsague J. Usage patterns of diclofenac and other selected systemic NSAIDs in the United States: results from a retrospective cohort of new users. Poster presented at the IASP World Congress on Pain 2016; September 27, 2016. Yokohama, Japan.
Margulis AV, Varas-Lorenzo C, Bui CL, McQuay LJ, Ziemiecki R, Reynolds M, Rebordosa C, Pladevall-Vila M, Fortuny J, Rivero-Ferrer E, Plana E, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS). Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
Martin-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia-Rodriguez LA. Risk factors for diabetic retinopathy in people with type 2 diabetes: a case-control study in a UK primary care setting. Prim Care Diabetes. 2016 Aug;10(4):300-8. doi: 10.1016/j.pcd.2016.01.002.
Martín-Merino E, Fortuny J, Rivero-Ferrer E, García-Rodríguez LA. Incidence of retinal complications in a cohort of newly diagnosed diabetic patients. PLoS One. 2014 Jun 25;9(6):e100283.
Groenwold R, Uddin M, Roes K, de Boer A, Rivero-Ferrer E, Martin E, Gatto N, Klungel O. Instrumental variable analysis in randomized trials with non-compliance and observational pharmacoepidemiologic studies. OA Epidemiology. 2014 May 9;2(1):9.
Sabate M, Pacheco JF, Ballarín E, Ferrer P, Petri H, Hasford J, Schoonen MW, Rottenkolber M, Fortuny J, Laporte JR, Ibanez L. A compilation of research working groups on drug utilisation across Europe. BMC Res Notes. 2014;7:143.
López-León S, Rivero E. Statins for prevention of alzheimer's disease: systematic review and meta-analysis. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal, Spain.
Groenwold RH, Klungel OH, Altman DJ, van der Graaf Y, Hoes AW, Moons KG, Rivero E, Fortuny J, PROTECT WP2. Adjustment for continuous confounders: an example of how to prevent residual confounding. Can Med Assoc J. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592
Seeger JD, Quinn S, Earnest DL, Lembo A, Kuo B, Rivero E. The zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol. 2012 Dec;12(1):171.
Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Risk factors for incident diabetic retinopathy in type II diabetes in UK primary care. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; June 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):S3.
Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Validation of diabetic retinopathy and maculopathy diagnoses recorded in a United Kingdom primary care database. Presented at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):S164-5.
Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Incidence of diabetic maculopathy among patients with diabetic retinopathy. Poster presented at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):S272.
Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Risk factors for incident diabetic macular edema in type II diabetes in UK primary care. Poster presented at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):S272-3.
Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Validation of diabetic retinopathy and maculopathy diagnoses recorded in a UK primary care database. Diabetes Care. 2012 Apr;35(4):762-7.